Original Article
miR-590-5p affects chondrocyte proliferation, apoptosis, and inflammation by targeting FGF18 in osteoarthritis

Peng Jiang¹, Xixi Dou², Shuaiguang Li³, Qingwen Jia², Peixue Ling⁵, Hongyu Liu⁴, Qiuju Han⁵, Shui Sun¹

¹Department of Orthopaedics, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China; ²Shandong Provincial Key Laboratory of Transmucosal and Transdermal Drug Delivery, Shandong Freda Pharmaceutical Group Co., Ltd., Jinan, Shandong Province, China; ³Department of Pharmacy, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; ⁴Prosit Sole Biotechnology, A302, No. 5 Kaituo Road, Haidian District, Beijing, China; ⁵Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China

Received March 8, 2021; Accepted June 25, 2021; Epub August 15, 2021; Published August 30, 2021

Abstract: Objective: To investigate the potential miRNA targeting FGF18, and its role in regulating the proliferation, apoptosis and inflammation in human primary chondrocytes. Methods: The normal human chondrocytes were induced by IL-1β to mimic OA in vitro. qPCR and Western blotting were performed to evaluate the expression of FGF18. Target Scan analysis was performed to predict the miRNA targeting FGF18. Then, the expression of miR-590-5p was quantified by qPCR in IL-1β-induced chondrocytes. After transfection of miR-590-5p mimics or inhibitors, CCK-8 assay was conducted to determine the cell viability and apoptosis-related proteins, and cartilage degeneration related biomarkers were assayed by qPCR and Western blotting. The levels of tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-8 were determined by ELISA. The targeting relationship between miR-590-5p and FGF18 was assayed by luciferase reporter assay in IL-1β-induced chondrocytes. Results: Target Scan analysis predicted that FGF18 is directly targeted by miR-590-5p. miR-590-5p was up-regulated, whereas FGF18 expression was inhibited in IL-1β-induced chondrocytes. After transfection of miR-590-5p mimics or inhibitors, CCK-8 assay was conducted to determine the cell viability and apoptosis-related proteins, and cartilage degeneration related biomarkers were assayed by qPCR and Western blotting. The levels of tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-8 were determined by ELISA. The targeting relationship between miR-590-5p and FGF18 was assayed by luciferase reporter assay in IL-1β-induced chondrocytes. Results: Target Scan analysis predicted that FGF18 is directly targeted by miR-590-5p. Results: miR-590-5p mimics reduced the expression of FGF18 protein, inhibited the cell viability of chondrocytes, and promoted secretion of inflammatory factors in chondrocytes, while miR-590-5p inhibitors increased FGF18 levels in IL-1β-treated chondrocytes. Furthermore, expression of inflammatory factors in chondrocytes was reduced by miR-590-5p inhibitors. The luciferase reporter assay showed that miR-590-5p could target FGF18. Conclusions: miR-590-5p promotes OA progression by targeting FGF18, which serves as a potential therapeutic target for OA.

Keywords: Chondrocytes, FGF18, miR-590-5p, osteoarthritis

Introduction

Osteoarthritis (OA) is a chronic inflammation-related joint disease with a complex pathogenesis. It often shows the symptoms of repeated attacks of joint pain, joint movement disorders and continuous aggravation [1, 2]. At present, there is no effective drug to prevent osteoarthritis associated with articular cartilage degeneration. It is well documented that several risk factors including aging, obesity, trauma, and genetic predisposition are associated with osteoarthritis, but the pathogenesis is not fully elucidated [3-5]. Chondrocytes are the only cells found in cartilage tissue that participate in the production of cartilage extracellular matrix (ECM), which plays an important role in the maintenance of cartilage structure and function [6, 7]. Therefore, it is of great significance to reveal the mechanism of chondrocyte injury and pathogenesis of OA.

It is well known that FGF18, a member of the fibroblast growth factor family, plays an important role in bone development, cartilage formation and osteogenesis during the growth period [8-10]. FGF18 has been shown to have significant anabolic effects on chondrocytes in carti-
miR-590-5p affects chondrocyte biologic behavior

Laginous tissues. More importantly, previous data suggested that lower expression of FGF18 may contribute to cartilage degradation [8]. Thus, FGF18 has been considered as a potential therapeutic target in the treatment of OA. According to the phase II clinical data published, recombinant human FGF-18 protein (rhFGF18) can effectively induce the proliferation of chondrocytes and promote the production of extracellular matrix, suggesting the good potential to promote the repair of joint diseases [11]. However, underlying mechanism for regulating FGF18 has not been fully elucidated.

Recently, FGF18 was demonstrated to be targeted by few miRNAs mainly in tumor models. miRNAs are highly conserved non-coding RNAs with a length of about 19-25 bp [12]. They can bind with the 3'UTR of target gene, thus regulating the expression of target gene at the post-transcriptional level [13, 14]. Of note, FGF-18 is overexpressed in many types of cancer and is demonstrated to promote tumor progression [15]. It is reported to be targeted by miR-590-5p and miR-139 in gastric cancer model and hepatocellular carcinoma cells [16, 17]. Until now, only few miRNAs including miR-21-5p and miR595 were identified to target FGF-18 during OA development [18, 19]. Whether other more miRNAs could regulate FGF-18 in chondrocytes and serve as potential target in OA still remains unclear.

In this present study, the miRNA target prediction was performed, then we investigated the expression levels of FGF18 and miR-590-5p in IL-1β-induced chondrocytes and investigated their influences on OA development, as well as the molecular mechanisms underlying miR-590-5p in OA in vitro. The results implied that miR-590-5p played a progressive role in OA, and it might be a potential therapeutic target for this disease.

Materials and methods

OA chondrocytes induced by IL-1β

The human chondrocyte cells (Procell, China) were induced by IL-1β to develop into IL-1β-induced chondrocytes. Cells were maintained in DMEM/F12 containing 10% fetal bovine serum (FBS, Gibco, USA) at 37°C in a humidified atmosphere of 5% CO₂ and 95% air, and the medium was changed every 2 days. The chondrocytes were plated to 6-well plates and cultured for 24 h. Then, these cells were stimulated with IL-1β (10 ng/mL, Peprotech, US) to produce a cellular OA model.

Cell transfection

Vectors and oligonucleotides were synthesized by and purchased from Guangzhou RiboBio Co., Ltd. The following vectors and oligonucleotides were used for transfection: miR-590-5p mimic (miR-590-5p, 5’-GAGCUUAUUCUAAAA GUGCAG-3’; 50 nM), mimic negative control (miR-NC, 5’-UUUGUACUACACAA AAGUACUG-3’; 50 nM), miR-590-5p inhibitor (in-miR-590-5p, 5’-CUGCACUUUU AUGAAUAAGCUC-3’; 100 nM), inhibitor control (in-miR-NC, 5’-GAGCUUAUUCU AAAAGUGCAG-3’; 100 nM), FGF18 overexpression vector (FGF; 50 nM), and FGF18 mutation overexpression vector (FGF18-mut; 50 nM). At 70% confluency, cells were transfected
miR-590-5p affects chondrocyte biologic behavior

Table 1. Primers sequence

<table>
<thead>
<tr>
<th>Species</th>
<th>Gene</th>
<th>Primer (5’ to 3’)</th>
<th>Primer (5’ to 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human</td>
<td>β-actin</td>
<td>F: CTCATCTGCGCCCTCGCTGT</td>
<td>R: GCTGTCACCTTCACCCTTCC</td>
</tr>
<tr>
<td>Human</td>
<td>Bax</td>
<td>F: CCGGTTGTCGCCCTTTTCTA</td>
<td>R: GAGGAATCCAGTTGCACTTCC</td>
</tr>
<tr>
<td>Human</td>
<td>Caspase-3</td>
<td>F: ACAAACAGGAAACCCCGTTGAT</td>
<td>R: GTACCATGCGAGCTGACATTCC</td>
</tr>
<tr>
<td>Human</td>
<td>Bcl-2</td>
<td>F: ATGGCCCTGGAGGATGCTGA</td>
<td>R: TAGACACGGAGGAAATAACAC</td>
</tr>
<tr>
<td>Human</td>
<td>ADAMTS5</td>
<td>F: CGGGATGCTTATGACTCTGTG</td>
<td>R: ACCGCCAGATAGAGTTGCTC</td>
</tr>
<tr>
<td>Human</td>
<td>Collagen II</td>
<td>F: CTATGCCAGCTGCTTCTACA</td>
<td>R: ACCACGTCACCTCTGGGT</td>
</tr>
<tr>
<td>Human</td>
<td>FGF-18</td>
<td>F: CAAGGAGTGGCGGTTCATGAGA</td>
<td>R: CGGGATGCTTATGACTCTGTG</td>
</tr>
</tbody>
</table>

using Lipofectamine® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol.

**qRT-PCR assay**

Total RNA was extracted using RNA isolater Totol RNA Extraction Reagent (Vazyme, China). 1 µg of total RNA was then reversely transcribed into cDNA by means of the HiScript® II 1st Strand cDNA Synthesis Kit (Vazyme, China) in line with the manufacturer's instructions. PCR was performed on Light Cycler 480 system (Roche, Switzerland) and amplified detection was conducted using ChamQ SYBR qPCR Master Mix (Vazyme, China). The levels of miRNAs were measured by qRT-PCR using miDETECT A Track™ miRNA qRT-PCR Kit (Guangzhou RiboBio Co., Ltd.). The primers for miR-590-5p and U6 small nuclear RNA were obtained from RiboBio Company (Guangzhou, China). The sequences were covered by a patent. For the quantification of the relative expression of each mRNA and miRNA, the threshold cycle (Ct) values were normalized against the endogenous references β-actin and U6. The 2^-ΔΔCt method was used. The primer sequences are presented in Table 1.

**Cell viability assay**

Cell viability was determined by Cell Counting Kit-8 assay. After being stimulated by IL-1β, the chondrocytes were transfected with NC or miR-590-5p mimics/inhibitors, the CCK8 solution (10 µl/well) was added to the culture medium. Then, after incubating for another 1 h at 37°C in humidified 95% air and 5% CO₂, the optical density (450 nm) was recorded.

**Enzyme-linked immunosorbent assay (ELISA)**

Culture supernatant was collected and the concentrations of TNF-α, IL-6 and IL-8 were measured by ELISA (Boster Biological Technology, China) following the manufacturer's instruction, and were normalized to cell protein concentrations.

**Dual luciferase report assay**

The binding sequences between miR-590-5p and FGF18 were predicted using Target Scan software. The FGF18 3'-untranslated region (3'-UTR) containing wild-type (WT) or mutant (MUT) binding sites for miR-590-5p (Guangzhou RiboBio Co., Ltd.) were inserted into a pmirGLO vector (Promega Corporation). Subsequently, the human FGF18 3'-UTR fragments and miR-590-5p were co-transfected into chondrocytes using Lipofectamine 3000 (Invitrogen). Transfection efficiency was normalized using the pRL-TK vector. A Dual Luciferase Assay Kit (Promega, USA) was used to measure luciferase activities at 48 h after transfection. Renilla luciferase activity was used for normalization.

**Western blot assay**

The chondrocytes in culture were lysed using the RIPA buffer (Beyotime Biotechnology, China). Total protein was separated by SDS-PAGE electrophoresis and transferred to 0.45 µm PVDF membranes. Membranes were blocked in TBS-T buffer containing 5% nonfat milk for 1 h and incubated overnight at 4°C with the following primary antibodies: FGF18 (#ab169615, Abcam, 1:1000), anti-Bcl2 (#ab-117115, Abcam, 1:1000), anti-Bax (#ab1827-33, Abcam, 1:1000), anti-caspase 3 (#ab321-50, Abcam, 1:1000), anti-ADAMTS5 (#ab41037, Abcam, 1:1000), anti-collagen II (#ab188570, Abcam, 1:1000), and β-actin (#ab8227, Abcam, 1:1000) was the internal control. Then the membranes were washed using TBST and hybridized with the horseradish peroxidase (HRP)-linked antibody goat anti-rabbit IgG.
miR-590-5p affects chondrocyte biologic behavior

Statistical analysis

SPSS 21.0 software was applied to analyze the data. The measurement data was expressed as mean ± standard deviation (SD). The statistical comparisons were performed using unpaired Student’s t test or one-way ANOVA. The enumeration data is presented as percentage or rate, and chi-square test was used for the comparison between two groups. P < 0.05 was determined significant difference.

Results

miR590-5p was upregulated in IL-1β-treated chondrocytes and was predicted to bind with FGF18 transcripts

To investigate the role of miR-590-5p in IL-1β-treated OA model, chondrocytes were transfected with miR-590 mimics. After transfection with miR590-5p mimics for 24 h, qPCR revealed that the expression level of miR590-5p was significantly upregulated in IL-1β-induced human chondrocytes (Figure 2A). Furthermore, we found that the expression of miR-590-5p, predicted to bind to the FGF18 transcripts, was promoted in IL-1β-stimulated human chondrocyte cells.

miR590-5p mimics inhibited the cell viability and promoted apoptosis of IL-1β-induced chondrocytes
miR-590-5p affects chondrocyte biologic behavior
miR-590-5p affects chondrocyte biologic behavior

Figure 2. miR590-5p was predicted to bind with the FGF18 transcripts. A: Four different algorithms, including mitarget scan, miRIP, microRNA.org, and miRDB were used to predict FGF18 mRNA-binding miRNA candidates; B: miR-590-5p was assayed by qPCR after IL-1β treatment for 24 h in human chondrocytes; C: The binding sites between miR-590-5p and the 3’UTR region of FGF18 predicted by PITA/miRanda. ***P < 0.001 versus control; **P < 0.01, 10 ng/mL versus 30 ng/mL.

Figure 3. miR590-5p overexpression inhibited the cell viability and promoted apoptosis of IL-1β-induced chondrocytes. Human chondrocytes were treated with 10 ng/mL IL-1β, and then transfected with NC or miR590-5p mimics (100 nM) for 24 h. A: miRNA-590-5p was detected by RT-PCR assay. B: Cell viability was determined using the CCK-8 assay. C: The mRNA levels of Bcl-2, Bax and Caspase-3 were detected by RT-PCR assay. D: Western blot analysis was carried out to detect Bcl-2, Bax and Caspase-3. E: Bar graph shows quantification results for Bcl-2, Bax and Caspase-3. *P < 0.05, **P < 0.01 and ***P < 0.001; #P < 0.05, ##P < 0.01, IL-1β+ mimics versus IL-1β mimics NC.
miR-590-5p affects chondrocyte biologic behavior

compared with cells treated with IL-1β alone or cells transfected with the negative control (Figure 3B).

To further determine the effects of the miR-590-5p on cell apoptosis of chondrocytes, the apoptosis of chondrocytes was induced by IL-1β (10 ng/ml) to mimic the pathological conditions of OA, and pro-apoptotic and anti-apoptotic genes were assayed. Importantly, the mRNA level of pro-apoptotic genes (Bax, caspase-3) in groups co-treated with IL-1β and miR-590-5p mimics was higher than that in groups incubated with IL-1β alone, while the expression of the anti-apoptotic protein Bcl-2 was decreased after miR590-5p treatment (Figure 3C). Alternatively, we obtained a similar result when detecting the protein levels of Bax, caspase-3 and Bcl-2 (Figure 3D, 3E). These data indicated that miR590-5p mimics inhibited the cell viability and promoted apoptosis of IL-1β-treated chondrocytes.

miR590-5p inhibitors increased the cell viability and inhibited apoptosis of IL-1β-induced chondrocytes

To further investigate the effect of miR-590-5p on IL-1β-stimulated human chondrocytes cells, miR-590-5p inhibitors were transfected. As shown in Figure 4A, the expression of miR-590-5p was dramatically decreased as compared to NC group. By using CCK-8 assay, we found that miR-590-5p inhibitors rescued the inhibition of proliferation induced by IL-1β (Figure 4B). Moreover, IL-1β notably upregulated the mRNA levels of Bax and caspase 3, and downregulated the mRNA level of Bcl-2 in human chondrocytes; however, these IL-1β-induced changes in apoptosis-related protein expressions were reversed following transfection with miR-590-5p inhibitors (Figure 4C). Furthermore, we obtained the similar results when detected the protein levels of Bax, caspase-3 and Bcl-2 (Figure 4D, 4E). These results indicated that miR590-5p inhibitors could increase cell viability and inhibit apoptosis of IL-1β-induced human chondrocytes cells.

miR590-5p regulated inflammatory response and cartilage degeneration related biomarkers in IL-1β-induced chondrocytes

To investigate whether miR-590-5p could regulate IL-1β-induced inflammatory injury in human chondrocytes, ELISA was used to detect the relevant indicators. As shown in Figure 5A-C, IL-1β significantly increased the levels of IL-6, IL-8 and TNF-α in the supernatants of human chondrocytes. Moreover, these IL-1β-induced changes were further promoted by miR-590-5p overexpression (Figure 5A-C). However, IL-1β-induced inflammatory responses were reversed by miR-590-5p inhibition, as the enhancement of TNF-α, IL-6, and IL-8 secretion was inhibited by miR-590-5p inhibitors (Figure 5D-F). These results illustrated that miR-590-5p could promote IL-1β-induced inflammatory response in human chondrocytes cells.

In addition, qPCR and Western blot were used to analyze the mRNA and protein levels of cartilage degeneration related biomarkers, including ADAMTs5 and collagen II. We found that IL-1β treatment reduced the expression of ADAMTs5 and collagen II, and miR-590-5p mimics further decreased the expression of these two genes at mRNA and protein levels (Figure 6A, 6B). Moreover, ADAMTs5 and collagen II levels downregulated by IL-1β were further reversed by miR-590-5p inhibitors (Figure 6C, 6D). These data suggested that miR-590-5p modulated cartilage degeneration related biomarkers in IL-1β-treated chondrocytes.

FGF18 was proved to be a direct target of miR-590-5p in chondrocytes

The luciferase reporter assay was performed to validate whether FGF18 expression was directly modulated by miR-590-5p via interactions with potential binding sites in IL-1β-induced chondrocytes. As shown in Figure 7A, perfect base paring was found between the seed sequence of miR-590-5p and the 3’UTR of FGF18. The results showed that human chondrocyte cells co-transfected with miR-590-5p mimic and WT FGF18 presented a significant decrease in luciferase activity in comparison with miR-NC group (Figure 7B). There was no obvious change in the luciferase activity in MUT FGF18 group either transfected with miR-590-5p mimic or miR-NC. Moreover, miR-590-5p inhibitors significantly promoted the luciferase activity of WT-FGF18, rather than MUT-FGF18 (P < 0.05) (Figure 7C). Furthermore, miR-590-5p mimics conspicuously down-regulated the mRNA and protein expressions of FGF18 in IL-1β-treated human chondrocytes (P < 0.05).
miR-590-5p affects chondrocyte biologic behavior

Figure 4. miR590-5p inhibition promoted the cell viability and inhibited apoptosis of IL-1β-induced chondrocytes. Human chondrocytes were treated with 10 ng/mL IL-1β, and then transfected with NC or miR590-5p inhibitors (100 nM) for 24 h. A: The expression of miRNA-590-5p was detected by qPCR assay. B: CCK-8 assay was performed to evaluate the viability of chondrocytes cells. C: The mRNA levels of Bcl-2, Bax and Caspase-3 were detected by RT-PCR assay. D: Western blot analysis was carried out to detect Bcl-2, Bax and Caspase-3. E: Bar graph shows quantification results for Bcl-2, Bax and Caspase-3. *P < 0.05, **P < 0.01 and ***P < 0.001; #P < 0.05, ##P < 0.01, ###P < 0.01, IL-1β+ inhibitors versus IL-1β+ inhibitors NC.
miR-590-5p affects chondrocyte biologic behavior

(Figure 7D-F), while miR590-5p inhibitors upregulated the mRNA and protein levels of FGF18 in IL-1β-treated human chondrocytes (P < 0.05) (Figure 7E, 7F). These data suggested that miR-590-5p directly regulated human chondrocytes expression through binding to FGF18 3’-UTR sequence.

Discussion

In the current study, we observed a significant downregulation of FGF18 and upregulation of miR-590-5p in IL-1β-treated human chondrocytes compared with the corresponding controls. Using an in vitro IL-1β-treated human chondrocyte model, we found that cell viability was strongly decreased, cell apoptosis and pro-inflammatory cytokines (TNF-α, IL-6 and IL-8) production were significantly increased in miR-590-5p-overexpressing cells compared to miR-NC cells, while miR-590-5p inhibitors produced the opposite results. Furthermore, luciferase activity validated that FGF18 was a target of miR-590-5p in chondrocytes.

miR-590-5p has been previously reported to be aberrantly expressed in several cancers and functioned as an onco-miR or an anti-onco-miR in various types of cancers including colorectal cancer and hepatocellular carcinoma [33, 34]. Notably, by acting on different target genes, miR-590-5p plays a different role in many pathophysiological processes, such as cellular proliferation and apoptosis. Accumulating evidence has suggested the importance of miR-590 in progression of human cervical cancer, colorectal cancer, lung adenocarcinoma, and gastric cancer [35, 36]. On the other hand, miR-590-5p has also been demonstrated to exert an anti-tumor role in colorectal cancer and breast cancer [33, 37]. In the present study, we...
miR-590-5p affects chondrocyte biologic behavior

Figure 6. miR-590-5p regulated cartilage degeneration related biomarkers in IL-1β-induced chondrocytes. Chondrocytes were treated with 10 ng/mL IL-1β, and then transfected with NC or miR590-5p mimics (100 nM) for 24 h. The mRNA (A) and protein (B) levels of ADAMTS5 and collagen II were detected by qPCR and Western blot. Then, human chondrocytes were treated with 10 ng/mL IL-1β, and then transfected with NC or miR590-5p inhibitors (100 nM) for 24 h, qPCR and Western blot were conducted to determine the mRNA (C) and protein (D) levels of ADAMTS5 and collagen II. *P < 0.05, **P < 0.01 and ***P < 0.001; #P < 0.05, ##P < 0.01 and ###P < 0.001, IL-1β+ mimics or inhibitors versus IL-1β+ NC.
observed that the expression of miR590-5p was significantly increased in IL-1β-treated chondrocytes, which indicates involvement of miR-590-5p in the pathogenesis of OA. To determine the function of miR-590-5p in OA, we used mimics and inhibitors to manipulate the expression of miR590-5p. We observed that miR-590-5p over-expression remarkably
miR-590-5p affects chondrocyte biologic behavior

reduced viability and significantly induced the secretion of inflammatory factors (IL-6, IL-8, and TNF-α) in IL-1β-treated chondrocytes, while miR-590-5p inhibitors could reverse these effects. In summary, we conclude that miRNA-590-5p may promote OA progression.

FGF18 is reported to be involved in chondrogenesis and cartilage repair with certain therapeutic effect and its mechanisms of action is supportive of evaluation for efficacy in osteoarthritis [9, 38, 39]. FGF18 can stimulate the proliferation and accumulation of type II collagen and proteoglycans in cultured porcine and adult human articular chondrocytes [8]. Previous studies demonstrated that FGF18 could stimulate the proliferation of chondrocytes through PI3K-AKT signaling in both monolayer and 3D culture and promote the accumulation of extracellular matrix (ECM) [9, 40]. Recently, FGF18 was demonstrated to be regulated by several miRNAs and was identified as a target of miRNAs, e.g., miR-19, miR-21-5p in human chondrocytes [18, 19], and miR-139 in hepatocellular carcinoma [17]. In the present study, we found that the levels of FGF18, ADAMTs5 and collagen II were significantly downregulated in IL-1β chondrocytes, miR-590-5p mimics further promoted the downregulation of these genes, while miR-590-5p inhibitors could reverse these effects. Luciferase reporter assay confirmed that FGF18 is a target of miR-590-5p in IL-1β-treated chondrocytes. Therefore, it was hypothesized that miR-590-5p inhibited the cell viability and promoted apoptosis of IL-1β-induced chondrocytes through targeting FGF18.

There are still some limitations existing in this study, such as insufficient sample, and single-center study. Subsequent studies will concentrate on the collection of an increased number of samples and animal experiments, and the multi-center study with long-term results. In addition, the effect of miR590-5p and FGF18 in the OA progression will be investigated by observing changes in indices at multiple time points, and to further confirm by a long-term follow-up study.

In summary, OA is a progressive degenerative disease characterized by cartilage degradation and chondrocyte apoptosis, the underlying mechanism may involve aberrant gene expressions and the associated responding biological events. In the present study, we connected miR-590-5p with the apoptosis, cell viability and FGF18 together, highlighting miRNA-590-5p silencing as an attractive therapeutic regimen in future clinical trials for OA patients.

Disclosure of conflict of interest

None.

Address correspondence to: Shui Sun, Department of Orthopaedics, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, No. 324, The Five Weft Seven Road, Jinan 250021, Shandong Province, China. Tel: +86-0531-8793-8911; Fax: +86-0531-87938911; E-mail: sunshui_oa@163.com; Qiuju Han, School of Pharmaceutical Sciences, Shandong University, No. 44, Wenhua West Road, Jinan 250101, Shandong Province, China. Tel: +86-0531-88381980; Fax: +86-0531-88381980; E-mail: hanqiuju@sdu.edu.cn

References


miR-590-5p affects chondrocyte biologic behavior


miR-590-5p affects chondrocyte biologic behavior


[40] Haanes KA and Edvinsson L. Pathophysiological mechanisms in migraine and the identification of new therapeutic targets. CNS Drugs 2019; 33: 525-537.